Sinovac Biotech
Sinovac Biotech's revenue rose 6.8% to $386 million in fiscal 2025. Its operating margin was −127.0%, up from −139.9% a year earlier. Free cash flow was −$561 million. It paid out $3.5 billion in dividends and buybacks.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2017 to 2024, earnings per share grew 16.0% a year and net income 6.7% a year, as new shares raised the share count by 26% and diluted each share's earnings. Sinovac Biotech then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 13,415 | 10,532 | 11,018 | 9,949 | 5,971 |
| Debt incl. finance leases | 16 | 12 | 254 | 376 | 495 |
| Net debt (negative means net cash) | −13,400 | −10,520 | −10,765 | −9,573 | −5,476 |
| Net debt to EBITDA | −0.8x | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.1x | 0.1x |
| Interest coverage | 6,212.4x | −402.7x | −144.5x | −89.7x | −49.9x |
| Current ratio | 5.9x | 9.0x | 9.0x | 7.3x | 4.6x |
| Quick ratio | 5.8x | 8.9x | 8.9x | 7.3x | 4.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 3 of 9 |
| Rule of 40 | −71.8% | −65.4% | −138.5% |
| Altman Z'' | 12.45 | 11.71 | 8.06 |
| Accruals ratio | −1.1% | 0.8% | 3.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 3 of 9 | 2 of 9 | 3 of 9 |
Compare
Put Sinovac Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Sinovac Biotech | FY25 | 6.8% | −127.0% | −145.4% | — | — | 3 | |
| Arcutis Biotherapeutics | FY25 | 91.3% | −3.2% | −1.7% | −16.9% | — | 4 | Compare |
| Pharming Group | FY25 | 26.6% | 6.9% | 14.3% | — | — | — | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
| Innoviva | FY25 | 14.7% | 39.8% | 47.6% | 17.9% | — | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 72 | 174 | 230 | 246 | 511 | 19,365 | 1,473 | 470 | 361 | 386 |
| Revenue growth | 7.4% | 140.7% | 31.7% | 7.1% | 107.5% | 3,692.5% | −92.4% | −68.1% | −23.1% | 6.8% |
| Gross profit | 50 | 154 | 205 | 214 | 443 | 18,376 | 815 | 323 | 221 | 262 |
| Research and development | 13 | 20 | 22 | 24 | 49 | 153 | 479 | 350 | 271 | 216 |
| Operating income | 0 | 45 | 45 | 69 | 216 | 17,618 | −509 | −714 | −506 | −490 |
| Net income | −1 | 26 | 22 | 45 | 110 | 8,122 | 14 | −14 | 41 | −199 |
| Diluted EPS (US$) | −0.01 | 0.45 | 0.34 | 0.41 | 0.97 | 113.44 | 0.20 | −0.19 | 1.27 | −0.83 |
| Diluted shares (millions) | 57 | 57 | 65 | 110 | 114 | 72 | 72 | 72 | 72 | 72 |
| Cash flow | ||||||||||
| Cash from operations | −14 | 60 | 8 | 39 | 479 | 15,322 | −798 | 139 | −57 | −512 |
| Capital expenditure | 13 | 12 | 6 | 11 | 128 | 594 | 314 | 156 | 96 | 49 |
| Free cash flow | −27 | 48 | 2 | 28 | 352 | 14,728 | −1,112 | −18 | −153 | −561 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 1,876 | 247 | 328 | 947 | 3,534 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 14 |
| Stock-based compensation | 2 | 1 | 4 | 3 | 10 | 8 | 0 | 0 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 62 | 114 | 177 | 203 | 1,176 | 13,415 | 10,532 | 11,018 | 9,949 | 5,971 |
| Debt incl. finance leases | 41 | 33 | 7 | 6 | 35 | 16 | 12 | 254 | 376 | 495 |
| Total assets | 211 | 299 | 370 | 452 | 1,901 | 16,759 | 14,030 | 13,612 | 12,337 | 8,542 |
| Total liabilities | 82 | 122 | 78 | 100 | 781 | 3,206 | 1,787 | 1,970 | 2,044 | 2,146 |
| Shareholders' equity | 116 | 151 | 253 | 294 | 746 | 8,995 | 8,491 | 8,316 | 8,262 | 4,439 |
| Margins and ratios | ||||||||||
| Gross margin | 69.1% | 88.4% | 89.2% | 86.8% | 86.8% | 94.9% | 55.3% | 68.8% | 61.1% | 67.9% |
| Operating margin | 0.7% | 26.1% | 19.7% | 27.9% | 42.2% | 91.0% | −34.5% | −151.9% | −139.9% | −127.0% |
| Net margin | −0.8% | 14.8% | 9.5% | 18.3% | 21.6% | 41.9% | 1.0% | −2.9% | 11.2% | −51.5% |
| Free cash flow margin | −36.7% | 27.4% | 1.0% | 11.6% | 68.9% | 76.0% | −75.5% | −3.7% | −42.3% | −145.4% |
| Rule of 40 (growth + FCF margin) | −29.2% | 168.2% | 32.7% | 18.7% | 176.4% | 3,768.5% | −167.9% | −71.8% | −65.4% | −138.5% |
| Return on capital | — | 36.3% | 32.3% | 45.5% | — | — | — | — | — | — |
| Return on equity | −0.5% | 19.3% | 10.8% | 16.4% | 21.2% | 166.8% | 0.2% | −0.2% | 0.5% | −3.1% |
| Return on assets | −0.3% | 10.1% | 6.5% | 10.9% | 9.4% | 87.0% | 0.1% | −0.1% | 0.3% | −1.9% |
| Net debt to EBITDA | −3.9x | −1.6x | −3.4x | −2.7x | −5.2x | −0.8x | — | — | — | — |